Ripple’s Senior Director of Engineering, J. Ayo Akinyele, has announced a significant privacy upgrade for the XRP Ledger (XRPL). In a blog post published in October 2025, Akinyele explained that the goal is to protect sensitive transaction details while still following global regulations. Akinyele shared the full roadmap in the official blog post, describing how […]Ripple’s Senior Director of Engineering, J. Ayo Akinyele, has announced a significant privacy upgrade for the XRP Ledger (XRPL). In a blog post published in October 2025, Akinyele explained that the goal is to protect sensitive transaction details while still following global regulations. Akinyele shared the full roadmap in the official blog post, describing how […]

Ripple Announces Major Privacy Upgrade For XRP Ledger – What To Know

2025/10/07 00:30
3 min read

Ripple’s Senior Director of Engineering, J. Ayo Akinyele, has announced a significant privacy upgrade for the XRP Ledger (XRPL). In a blog post published in October 2025, Akinyele explained that the goal is to protect sensitive transaction details while still following global regulations. Akinyele shared the full roadmap in the official blog post, describing how the upgrade will help users protect sensitive data while staying within regulatory boundaries. 

Ripple Introduces Zero-Knowledge Proof Roadmap For Enhanced Privacy

In his October 2025 blog post, J. Ayo Akinyele outlined Ripple’s new zero-knowledge proof (ZKP) roadmap for the XRP Ledger. According to the roadmap, there are two main steps in this latest upgrade. The first step, planned for the next 12 months, will add private and compliant transactions to XRPL using zero-knowledge technology. With this upgrade on the XRP ledger, businesses can conduct transactions privately while still complying with financial laws. The second step, set for 2026, will introduce Confidential Multi-Purpose Tokens (MPTs). 

These MPTs will enable the representation of real-world assets, such as real estate, commodities, or company shares, to be stored on the XRPL while maintaining the confidentiality of sensitive ownership details. A bank, for example, could confirm a transaction is valid without revealing its complete information to competitors or the public. 

The upgrades, described by Ripple as essential features for “programmable privacy,” would allow users to choose how, when, and with whom they share their data. The flexible design could raise the standard for how digital ledgers can balance openness with security and meet the growing need for secure and regulation-friendly blockchain systems. 

Institutional Adoption And XRPL 3.0: Setting New Standards For Compliance

Ripple’s engineers say the goal of the upgrade is to make XRPL a stronger and more compliant platform for financial institutions. A significant part of this effort is the Multi-Purpose Token (MPT) standard, which Akinyele confirmed officially went live on the XRPL mainnet in October 2025. The current version enables tokenized assets, such as property or commodities, to exist natively on the ledger. The next version, expected in 2026, will extend this framework into fully confidential tokens, supporting private asset trading and settlement.

Along with these privacy tools, Akinyele also noted that Ripple’s engineering team is preparing a native lending protocol for XRPL Version 3.0.0, which will support decentralized credit and liquidity pooling. The new lending protocol will bring borrowing, lending, and trading directly onto the XRP ledger. The roadmap reflects Ripple’s plan to strengthen XRPL’s appeal to institutions by building a secure and regulation-ready network for the years ahead.

Through the privacy and tokenization upgrades on the XRP Ledger, Ripple moves closer to building an enterprise-grade blockchain that strikes a balance between privacy, compliance, and real-world functionality.

Ripple price chart from Tradingview.com (XRP Ledger)
Market Opportunity
Major Logo
Major Price(MAJOR)
$0.08387
$0.08387$0.08387
-0.61%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26